Luiz Belardinelli, M.D.
Chief Medical Officer
Dr. Belardinelli was the Senior Vice President for the Cardiovascular Therapeutics of Gilead from May 2009 until July 2015. Previously, he served as Senior Vice President for Clinical Research and Pharmacology, and Translational Biomedical Research, as well as other positions at CV Therapeutics from 1999 until 2009, when the company was acquired by Gilead.
Dr. Belardinelli received an MD from the Medical Catholic School of Porto Alegre, Brazil in 1975, and completed a four-year postdoctoral research fellowship in the Department of Physiology at the University of Virginia. Subsequent academic appointments included Assistant and Associate Professor of Medicine, Division of Cardiology, University of Virginia (1980-1988), and Professor of Medicine (Cardiology) and Pharmacology and Eminent Scholar of Cardiovascular Research, University of Florida (1988-1999). Dr. Belardinelli is a recognized expert in cardiac electrophysiology, adenosine physiology and pharmacology, and played a key role in the development and approval for human uses of Adenocard, Lexiscan and Ranexa. He holds several awards including “Inventor of the Year” by the Alumni Association of the University of Virginia. He has authored or co-authored 376 publications and is the co-editor of 3 books.